In 448 neuroendocrine tumor patients, PRRT with ¹⁷⁷Lu-DOTATATE showed similar renal toxicity but more hematological effects compared to ⁹⁰Y-DOTATOC, while achieving significantly longer progression-free survival.
HR 0.47 for PFS¹⁷⁷Lu-DOTATATE nearly doubled progression-free survival compared to ⁹⁰Y-DOTATOC in 448 neuroendocrine tumor patients
What the researchers found
Among 448 NET patients, ¹⁷⁷Lu-DOTATATE (n=335) showed no significant renal toxicity difference from ⁹⁰Y-DOTATOC (n=113) but caused more hematological effects. ¹⁷⁷Lu-DOTATATE was associated with significantly longer PFS (HR 0.47, P=0.004) but no OS difference.
Why it matters
PRRT is a mainstay of neuroendocrine tumor treatment, and choosing between ¹⁷⁷Lu and ⁹⁰Y agents involves balancing efficacy against toxicity. This large real-world comparison provides evidence that ¹⁷⁷Lu-DOTATATE offers superior tumor control with manageable side effects.
The numbers in context
448 patients across two US centers. Both 177Lu-DOTATATE and 90Y-DOTATOC forms of PRRT analyzed. Kidney and blood toxicity tracked over treatment course.
How the study worked
Retrospective cohort of 448 NET patients (335 ¹⁷⁷Lu-DOTATATE, 113 ⁹⁰Y-DOTATOC). Renal function tracked via creatinine, BUN, eGFR. Hematological function via WBC, platelets, hemoglobin. Piecewise linear mixed-effect models for longitudinal data. Cox proportional hazard regression for OS and PFS.
Who was studied
Neuroendocrine tumor patients at two US medical centers
What this study cannot tell us
Retrospective design with potential selection bias. The two treatment groups may differ in baseline characteristics. Long-term renal effects beyond the follow-up period weren't captured. The study doesn't account for prior or concurrent therapies.
How to read the evidence
Moderate evidence from a large retrospective cohort (448 patients). While the sample size is substantial, the non-randomized design limits causal conclusions.
When this study was published
Published in 2024; reflects current clinical experience with PRRT in neuroendocrine tumors.
The bigger picture
PRRT represents one of the most successful applications of peptide-based targeted therapy in oncology. As more radiopharmaceuticals enter development, understanding the toxicity-efficacy tradeoff of different radioligands helps optimize treatment selection and monitoring for cancer patients.
Questions still open
- Would combining both agents sequentially or in tandem improve outcomes while managing toxicity?
- What patient characteristics predict hematological toxicity from ¹⁷⁷Lu-DOTATATE?
- Does the PFS advantage of ¹⁷⁷Lu-DOTATATE eventually translate to improved overall survival with longer follow-up?
Common questions
What is PRRT and how does it work?
Should I be worried about kidney damage from PRRT?
Read the original research
Peptide Receptor Radionuclide Therapy and clinical associations with renal and hematological toxicities and survival in patients with neuroendocrine tumors: an analysis from two U.S. medical centers.
Journal of cancer research and clinical oncology, 150(11), 485
Citation
Xu, Tao; Dillon, Joseph S; Maluccio, Mary A; Quelle, Dawn E; Nash, Sarah H; Cho, Hyunkeun; Limbach, Kristen E; Skill, Nicholas J; Bren-Mattison, Yvette; O'Rorke, Michael A. (2024). Peptide Receptor Radionuclide Therapy and clinical associations with renal and hematological toxicities and survival in patients with neuroendocrine tumors: an analysis from two U.S. medical centers.. Journal of cancer research and clinical oncology, 150(11), 485. https://doi.org/10.1007/s00432-024-06020-w